The goal of this clinical study is to learn more about the study drug lenacapavir (LEN), safety, tolerability, and pharmacokinetics (how LEN is absorbed, modified, distributed, and removed from the body of the participants) of once-yearly intramuscular for HIV pre-exposure prophylaxis (PrEP) in people with an indication for PrEP. The primary objective of this study is to evaluate the pharmacokinetics (PK) and the safety and tolerability of intramuscular (IM) every 12 months (Q12M) LEN for PrEP among people with an indication for PrEP.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
339
Administered intramuscularly
Administered orally
Plasma LEN Ctrough at Week 52
Ctrough is defined as the concentration at the end of the dosing interval.
Time frame: Week 52
Percentage of Participants Experiencing Treatment-emergent Adverse Event (TEAEs)
Time frame: First dose up to 30 days post last dose (approximately 3 years)
Percentage of Participants Experiencing Treatment-emergent Clinical Laboratory Abnormalities
Time frame: First dose up to 30 days post last dose (up approximately 3 years)
Percentage of Participants With Discontinuation due to Adverse Event
Time frame: First dose up to 30 days post last dose (approximately 3 years)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
UAB Sexual Health Research Clinic
Birmingham, Alabama, United States
UCLA Clinic Care
Los Angeles, California, United States
Ruane Clinical Research Group, Inc.
Los Angeles, California, United States
UCLA Vine Street Clinic
Los Angeles, California, United States
Mills Clinical Research
Los Angeles, California, United States
BIOS Clinical Research
Palm Springs, California, United States
UCSD AntiViral Research Center (AVRC)
San Diego, California, United States
Bridge HIV, San Francisco Department of Public Health
San Francisco, California, United States
Yale University; School of Medicine; AIDS Program
New Haven, Connecticut, United States
Whitman-Walker Institute, Inc.
Washington D.C., District of Columbia, United States
...and 21 more locations